Controversies Continue in NCCN Ovarian Cancer Guidelines

Medscape Medical News from the:  

National Comprehensive Cancer Network (NCCN) 17th Annual Conference

This coverage is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.

From Medscape Medical News > Conference News

Controversies Continue in NCCN Ovarian Cancer Guidelines

Neoadjuvant Chemotherapy and CA-125 Reviewed

March 20, 2012 (Hollywood, Florida) — The ovarian cancer guidelines from the National Comprehensive Cancer Network (NCCN) address a number of ongoing controversies, according to a presenter here at the NCCN 17th Annual Conference.

 

"There have not been a lot of changes in the past year, but there are various areas of controversy in the guidelines," Robert Morgan, MD, from the City of Hope Comprehensive Cancer Center in Los Angeles, California, told Medscape Medical News at the conference.
One such controversy is about the usefulness of the biomarker CA-125 to monitor patients who have been treated with surgery and/or chemotherapy. Dr. Morgan called CA-125 the "most controversial" aspect of patient follow-up.......

2009 Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future | PeerView Press

(free) viewing:
Includes: Dr's Markman, Armstrong & Coleman


Topics:

• Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future  
• Taking Stock of the Current Research: Which New Therapies Are Showing Promise in Ovarian Cancer?   
• Audio - Q&A Lightning Round: Expert Opinions on Unanswered Questions and Controversies in Ovarian Cancer